Dec 06, 2023
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2023-- 2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the Company”), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: As we indicated last month, the Board
Nov 20, 2023
PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 20, 2023-- Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental
Aug 01, 2023
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will present at the upcoming 2023 Wedbush PacGrow Healthcare Conference on August 8, 2023 at 8:00am ET in New